Carbapenem-Resistant Acinetobacter baumannii: From Molecular Mechanisms to Clinical Practice
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotic Therapy in Infectious Diseases".
Deadline for manuscript submissions: closed (31 December 2025) | Viewed by 2143
Special Issue Editors
Interests: clinical assessment; infectious disease treatment; MDR bacteria; emerging and tropical infectious diseases
Special Issues, Collections and Topics in MDPI journals
Interests: clinical trials; molecular and clinical epidemiology of infections
Special Issue Information
Dear Colleagues,
Acinetobacter baumannii has emerged as one of the most challenging multidrug-resistant pathogens in healthcare settings worldwide. In particular, carbapenem-resistant A. baumannii (CRAB) poses a serious threat due to its ability to acquire and disseminate resistance determinants, survive in harsh environments, and cause severe infections in vulnerable patients. The rise of CRAB has led to limited therapeutic options and increased morbidity and mortality, especially in intensive care units.
This Special Issue aims at exploring CRAB from a multidisciplinary perspective, ranging from molecular resistance mechanisms, genomic surveillance, and epidemiology to infection control strategies, clinical management, and novel therapeutic approaches. We invite original research articles, reviews, and case reports, that contribute to a deeper understanding of CRAB and support evidence-based clinical practice.
Prof. Dr. Antonio Cascio
Prof. Dr. David L. Paterson
Guest Editors
Dr. Luca Pipitò
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CRAB
- XDR
- MDR
- Acinetobacter baumannii
- antimicrobial resistance
- molecular mechanisms
- clinical practice
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
